We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Aperiomics Launches Novel NGS Services

By LabMedica International staff writers
Posted on 17 Nov 2014
Aperiomics (Ashburn, VA, USA), founded in October 2013 to bring ground-breaking solutions that address disease challenges, has launched its first commercial services with its breakthrough “Absolute-NGS Pathogen Detection Platform.” The platform consists of a novel set of 3 new-generation sequencing (NGS) services that provide unique tools for more effective identification of known and unknown microorganisms, focusing on pathogens.

The Absolute-ID service identifies known pathogens in virtually any sample. More...
The Absolute-Discover service can discover new pathogens. The Absolute-Biome service is designed to identify all microorganisms present in a given sample – such microbiome studies can help understand the impact of disease, drugs, or environmental changes.

Aperiomics, named after the Latin "aperio" meaning to reveal, is rolling out this package to provide laboratories, public health care, and businesses with better tools for rapid pathogen identification. The unique service addresses the biggest challenge in applying NGS to real-world analysis – making sense of the massive amount of data spawned by NGS. Aperiomics’ innovative technology uses an unbiased sequencing and genomic analysis approach. With their novel combination of genomics and informatics, the company capitalizes on high-throughput NGS and advanced Bayesian statistics to produce faster and better results than other approaches.

According to Jeff Gallagher, CEO of Virginia Bio, “Much of the promise of the future of health care and biomedical research depends on innovative use of data analytics. Done right, this will yield speed, power, and insights well beyond forerunner products and services based solely in biology and chemistry. It will open up unimaginable new opportunities to create value for patients worldwide. Aperiomics is a case in point.”

Aperiomics CEO Crystal Icenhour, PhD, explains the importance of these services: “The majority of pathogens are currently never identified. Thus, the advantages of accurate determination can be measured with improvements in human health, significant cost savings, and reduced risks to public health.”

The technology behind these Aperiomics’ services is the result of collaboration by three co-founders: The company’s president, Keith A. Crandall, PhD and director of the Computational Biology Institute at George Washington University; Chief Technology Officer W. Evan Johnson, PhD and assistant professor of Medicine, Biostatistics, and Bioinformatics at Boston University School of Medicine; and Chief Science Officer Eduardo Castro-Nallar, PhD in Biological Sciences from George Washington University.

Aperiomics is seeking additional funding to expand operations and service capacity.

Related Links:

Aperiomics



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.